氯喹与羟氯喹在治疗剂量或过量使用时的毒性
本文综述了氯喹和羟氯喹在短期治疗、长期治疗及过量时的毒性表现,检索了Medline(建库至2020年6月7日)和PubMed(至2020年6月10日),共纳入57篇原始文献及34篇COVID-19相关文献。短期使用最常见的毒性为胃肠道反应,心脏毒性(QT/QTc延长)在COVID-19治疗中尤受关注,尤其与阿奇霉素联用时;长期使用的主要剂量限制性毒性为视网膜病变,并与心脏传导异常、心肌病和神经肌肉毒性相关;过量时症状在数分钟至数小时内迅速出现,心血管虚脱和休克最为突出,死亡多源于心血管崩溃。
要点
- 短期使用氯喹或羟氯喹最常见毒性为胃肠道反应(恶心、呕吐、腹泻),多数报告的不耐受由此引起。
- COVID-19治疗中QT/QTc延长是短期心脏毒性关注点,尤其与阿奇霉素联用时,但研究间存在分歧。
- 长期使用的主要剂量限制性毒性为视网膜病变,风险随年龄、剂量和用药时长增加而升高。
- 过量时症状在数分钟至数小时内迅速出现,心血管虚脱和休克最突出,死亡多源于心血管崩溃。
- 葡萄糖-6-磷酸脱氢酶缺乏者使用氯喹或羟氯喹可能发生溶血和贫血。
适用人群与场景
- 使用羟氯喹治疗类风湿关节炎、系统性红斑狼疮等疾病的患者,以及使用氯喹治疗疟疾的患者。
- 2020年考虑使用羟氯喹(较少使用氯喹)治疗SARS-CoV-2感染(COVID-19)的患者。
红旗征与不能漏的情况
- 过量时症状在数分钟至数小时内迅速出现,心血管虚脱和休克最突出,死亡多源于心血管崩溃。
- 过量时可能出现精神病和癫痫等神经毒性效应。
- 短期使用可能产生心脏传导异常,COVID-19治疗中QT/QTc延长尤受关注,尤其与阿奇霉素联用时。
- 用药后24-48小时内可能出现意识模糊、定向障碍和幻觉等神经精神症状。
- 短期暴露后数天至数周内可能出现药疹或皮疹、皮肤色素沉着、瘙痒、Stevens-Johnson综合征和中毒性表皮坏死松解症。
研究设计与关键结果
- 本文为综述,检索Medline(建库至2020年6月7日)和PubMed(至2020年6月10日)等数据库,最终纳入57篇原始文献、34篇COVID-19相关文献和29篇药物相互作用相关文献。
- 短期使用:胃肠道毒性最常见;羟氯喹标准治疗剂量下血糖异常罕见;短期使用可产生心脏传导异常,COVID-19治疗中QT/QTc延长尤受关注,尤其与阿奇霉素联用,但研究间存在分歧。
- 短期使用:皮肤毒性可在暴露后数天至数周内出现,通常停药后缓解;神经精神症状可在用药后24-48小时内出现。
- 氯喹治疗COVID-19与肌酸激酶和肌酸激酶-MB活性升高相关,高剂量组事件更多。
- 长期使用:视网膜病变是主要剂量限制性毒性,风险随年龄、剂量和用药时长增加而升高;长期使用还与心脏传导异常、心肌病和瓣膜疾病相关;罕见肌炎、肌无力、肢体无力和假性帕金森综合征。
- 过量:症状在数分钟至数小时内迅速出现,心血管虚脱和休克最突出,神经毒性如精神病和癫痫也可能出现。
证据类型、等级与局限
- 证据类型:综述,检索并汇总了原始研究和COVID-19相关文献。
- 局限:原文未报告局限性。
对床旁实践的改变
- 羟氯喹是通常耐受良好的药物,短期(数天至数周)毒性包括胃肠道反应和罕见的血糖异常、皮肤反应及神经精神事件。
- 在COVID-19患者中使用羟氯喹时,心脏毒性成为更受关注的问题。
- 长期(数年)毒性包括视网膜病变、神经肌肉毒性和心脏毒性(传导异常、心肌病)。
- 过量死亡最常由心血管崩溃导致。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: While chloroquine, a derivative of quinine, has been used as an antimalarial for 70 years, hydroxychloroquine is now used to treat conditions such as rheumatoid arthritis and systemic lupus erythematosus. In 2020, hydroxychloroquine (and to a lesser extent chloroquine) also received attention as a possible treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). During investigation for treating coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, concerns for serious adverse events arose.
OBJECTIVE: We review the toxicity associated with hydroxychloroquine and chloroquine use both short-term and long-term and in overdose.
METHODS: Medline (via OVID) was searched from its inception through June 7 2020 using the following as either MeSH or keyword terms: ("Chloroquine/" or "Hydroxychloroquine/") AND ("Adverse Drug Event/" or "Toxicities, Drug/" or "Toxic.mp." or "Toxicity.mp." or "Overdose.mp."). We limited resultant articles to those published in English and reporting on Human subjects. This search yielded 330 articles, of which 57 were included. Articles were excluded due to lack of relevance, not reporting desired outcomes, or being duplicative in their content. Twenty-five additional articles were identified through screening references of included articles. To identify toxicities in individuals treated with hydroxychloroquine or chloroquine with COVID-19, we searched PubMed on June 10th, 2020: ("Chloroquine" or "Hydroxychloroquine") AND ("Coronavirus" or "COVID-19" or "SARS-CoV-2"). This search resulted in 638 articles. We reviewed articles for reporting of adverse events or toxicities. Most citations were excluded because they did not include original investigations or extrapolated data from subjects that did not have COVID-19; 34 citations were relevant. For the drug-interactions section, relevant classes and agents were identified through a screen of the https://www.covid19-druginteractions.org/ website. We then conducted targeted searches of PubMed up to June 7th 2020 combining "chloroquine" and "hydroxychloroquine" with terms for specific drug classes and drugs identified from the drug-interaction site as potentially relevant. We found 29 relevant articles.
TOXICITY WITH SHORT-TERM USE: Gastrointestinal: Gastrointestinal toxicities are the most common to occur following initiation of chloroquine or hydroxychloroquine. Nausea, vomiting, and diarrhea account for most reported intolerances. Glucose abnormalities: Alterations in blood glucose concentrations may occur with hydroxychloroquine but are rare with standard therapeutic use. Cardiotoxicity: Short-term use can produce conduction abnormalities. Evidence from COVID-19 treatment suggests QT/QTc prolongation is of concern, particularly when used in combination with azithromycin, although disagreement exists across studies. Dermatologic: Drug eruptions or rashes, followed by cutaneous hyperpigmentation, pruritis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, may occur within days to weeks of exposure but usually resolve with the discontinuation of therapy. Neuropsychiatric: Reported symptoms include confusion, disorientation, and hallucination within 24-48 h of drug initiation. Other toxicities: Hemolysis and anemia may occur in patients with glucose-6-phosphate dehydrogenase. Chloroquine treatment of COVID-19 was associated with elevation in creatine kinase and creatine kinase-MB activities with more events in the higher-dose group.
TOXICITY WITH LONG-TERM USE: Retinopathy: Retinopathy is the major dose-limiting toxicity associated with long-term use; the risk is higher with increasing age, dose, and duration of usage. Cardiotoxicity: Long-term use has been associated with conduction abnormalities, cardiomyopathy, and valvular disorders. Neurotoxicity: Rarely myositis and muscle weakness, extremity weakness, and pseudoparkinsonism have been reported.
TOXICITY IN OVERDOSE: Symptoms in overdose manifest rapidly (minutes to hours) and cardiotoxicity such as cardiovascular shock and collapse are most prominent. Neurotoxic effects such as psychosis and seizure may also occur.
CONCLUSIONS: Hydroxychloroquine is a generally well-tolerated medication. Short-term (days to weeks) toxicity includes gastrointestinal effects and rarely glucose abnormalities, dermatologic reactions, and neuropsychiatric events. Cardiotoxicity became of increased concern with its use in COVID-19 patients. Long-term (years) toxicities include retinopathy, neuromyotoxicity, and cardiotoxicity (conduction abnormalities, cardiomyopathy). Deaths from overdoses most often result from cardiovascular collapse.
参考来源
- Doyno C, Sobieraj DM, Baker WL, et al. Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. Clin Toxicol (Phila). 2020. PMID: 32960100. doi:10.1080/15563650.2020.1817479
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。